Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Moleculin Biotech (MBRX) Assets Average (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Assets Average data on record, last reported at $21.0 million in Q3 2025.

  • For Q3 2025, Assets Average fell 14.34% year-over-year to $21.0 million; the TTM value through Sep 2025 reached $21.0 million, down 14.34%, while the annual FY2024 figure was $27.6 million, 42.34% down from the prior year.
  • Assets Average reached $21.0 million in Q3 2025 per MBRX's latest filing, down from $21.3 million in the prior quarter.
  • Across five years, Assets Average topped out at $96.7 million in Q2 2021 and bottomed at $19.0 million in Q1 2025.
  • Average Assets Average over 5 years is $51.6 million, with a median of $49.1 million recorded in 2023.
  • Peak YoY movement for Assets Average: soared 240.04% in 2021, then crashed 48.14% in 2024.
  • A 5-year view of Assets Average shows it stood at $86.4 million in 2021, then dropped by 28.94% to $61.4 million in 2022, then crashed by 36.69% to $38.9 million in 2023, then crashed by 48.14% to $20.2 million in 2024, then grew by 4.04% to $21.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $21.0 million in Q3 2025, $21.3 million in Q2 2025, and $19.0 million in Q1 2025.